Risks
4 risks
Risk Intelligence
Sustained high crude prices hurting antibiotic demand
View Risks →Aarti Drugs Limited — Q4 FY26
Aarti Drugs reported Q4 FY26 consolidated revenue of ₹721.1 crore (+6% YoY) and EBITDA of ₹96.6 crore (13.4% margin).
neutral
medium
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Aarti Drugs reported Q4 FY26 consolidated revenue of ₹721.1 crore (+6% YoY) and EBITDA of ₹96.6 crore (13.4% margin). PAT declined 12% YoY to ₹55.3 crore due to elevated costs and ramp-up expenses. The methylamine plant achieved ~40% utilization in Q4, targeting 55-60% in Q1 FY27. Formulation revenue surged 41% YoY to ₹91.3 crore, driven by export growth. Management guided for 8-10% volume growth and 100-200 bps EBITDA margin improvement in FY27, contingent on stable crude prices. Key risks include sustained high crude impacting antibiotic demand and delayed salicylic acid turnaround.
आरती ड्रग्स ने वित्त वर्ष 2026 की चौथी तिमाही में ₹721.1 करोड़ का कारोबार किया, जो पिछले साल से 6% ज़्यादा है। कंपनी ने ₹96.6 करोड़ का EBITDA कमाया, यानी मुनाफे की दर 13.4% रही। लेकिन शुद्ध मुनाफा (PAT) 12% घटकर ₹55.3 करोड़ रह गया, क्योंकि लागत और नए काम के खर्चे बढ़े। मिथाइलामाइन प्लांट चौथी तिमाही में 40% क्षमता पर चला, अगली तिमाही में 55-60% तक पहुँचने का लक्ष्य है। फॉर्मूलेशन (दवा बनाने) का कारोबार 41% बढ़कर ₹91.3 करोड़ हुआ, जिसमें निर्यात ने बड़ी भूमिका निभाई। कंपनी को अगले वित्त वर्ष में 8-10% बिक्री बढ़ने और मुनाफे की दर में 1-2% सुधार की उम्मीद है, लेकिन यह कच्चे तेल की कीमतों पर निर्भर करेगा। अगर तेल महँगा रहा, तो एंटीबायोटिक की माँग घट सकती है और सैलिसिलिक एसिड के काम में देरी हो सकती है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Methylamine plant utilization
40%
+11pp QoQ
Ramped from ~29% in Q3 to >40% in Q4; targeting 55-60% in Q1 FY27.
Formulation revenue
₹91.3 crore
+41% YoY
Driven by direct exports in non-oncology portfolio; exports contributed 69%.
Regulated market export share
73%
+7pp YoY
Increased from 66% in FY25, reflecting shift towards higher-value markets.
Methylamine plant production rate (March 2026)
~1,000 tons/month
N/A
Achieved nearly 1,000 tons per month in March; key for metformin backward integration.
What Changed vs Last Quarter
NEW
Methylamine plant utilization target 55-60% in Q1 FY27
Management expects to cross 55-60% utilization in the June quarter, with a path to >70% within a year.
NEW
EBITDA margin target of 13.5-14% for FY27
Targeting EBITDA margins between 13.5% and 14% for FY27, assuming stable crude prices; without war, target was 14-14.5%.
NEW
Capex plan of ₹300-400 crore over 2-3 years
Planned capex for brownfield expansions and formulation capacity, including oncology, over the next 2-3 years.
UPDATED
Volume growth target of 8-10% for FY27
Management targets 8-10% volume growth, with internal aspirations of 10-15%, supported by new capacities.
DROPPED
EBITDA margin recovery to 12-13% near-term, 14-15% steady-state
Management targets EBITDA margin of 12-13% in the near term and 14-15% at steady state, driven by backward integration, export mix, and formulation ramp-up.
DROPPED
Sikar plant utilization to reach 50% by March 2026, 75% next quarter
Sikar facility expected to ramp to 50% utilization in Q4 FY26 and 75% in the subsequent quarter, with full utilization within 12 months.
DROPPED
Capex of ₹150-200 crore per year for next two years
Management guided for annual capex of ₹150-200 crore over the next two years, including oncology product development, brownfield expansions, and energy improvements.
NEW RISK
Sustained high crude prices hurting antibiotic demand
If crude remains above $110-120, domestic antibiotic demand may decline due to price sensitivity, impacting volumes.
NEW RISK
Salicylic acid plant turnaround delayed
Salicylic acid production remains shut due to equipment delays and variable losses; restart depends on successful installation and testing.
NEW RISK
Methylamine ramp-up dependent on metformin expansion
Higher utilization of the methylamine plant requires commensurate metformin production expansion, which is still underway.
NEW RISK
Geopolitical disruptions impacting raw material supply
West Asia war caused ammonia shortages in March; further escalation could disrupt key raw material availability.
RISK GONE
Continued Chinese dumping in salicylic acid
Chinese dumping persists, pressuring realizations. Management plans to file anti-dumping application by April 2026, but relief may take 6-8 months.
RISK GONE
Slow ramp-up of greenfield facilities
Salicylic acid plant ramp-up slower than expected due to technology changes and quality parameter adjustments, delaying profitability.
RISK GONE
Antibiotic demand weakness
Weaker antibiotic demand reduced overall market pool, leading to lower capacity utilization and margin pressure. Management noted this as a key headwind.
RISK GONE
High capex despite recent investments
Analyst raised concern about continued high capex (₹150-200 Cr/year) while new plants are still scaling up. Management defended citing smooth Sikar ramp-up and need for oncology investment.
🤫 Topics management stopped discussing
Mentioned in Q2 FY26, Q3 FY26
Management guided for annual capex of ₹150-200 crore over the next two years, including oncology product development, brownfield expansions, and energy improvements.
Mentioned in Q2 FY26, Q3 FY26
Weaker antibiotic demand reduced overall market pool, leading to lower capacity utilization and margin pressure. Management noted this as a key headwind.
Fast read
Guidance and risk preview
Management expects to cross 55-60% utilization in the June quarter, with a path to >70% within a year.
If crude remains above $110-120, domestic antibiotic demand may decline due to price sensitivity, impacting volumes.
View Risks →